Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials for Breast Cancer and Sarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.
Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at Biotech Conferences
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology embodied in its lead product, Rexin-G, the first targeted genetic medicine developed to treat metastatic cancer.Pharmaceutical Giants Take Aim at Tightening Productivity in Research and Development Using State-of-the Art Business Intelligence Tools
KENILWORTH, N.J. -- 3C Company, Inc. (www.3cpharma.com), a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence - 3C Company's Business Intelligence Solution for strategic and tactical oversight of their Research and Development portfolio.
Libutol™ All Natural 'Feel Good' Pill Strikes a Chord with Millions of Women
SALT LAKE CITY, Utah -- If the overwhelming response to the Libutol(TM) ad is any indication, it seems American women are more tired, distressed and unhappy than most experts (and women themselves) are willing to admit. That's the logical conclusion drawn from the phenomenal reaction women are having to Libutol, "The Little Yellow Pill That Makes Life Better" from Blackett Pharmacal.Campbell Belman Releases Comprehensive Report for Pharmaceutical Marketers
NEW YORK, N.Y. -- Campbell Belman's mission is to remove the uncertainty about marketing return-on-investment (ROI) for pharmaceutical companies; a new comprehensive report releases proven approaches for real and measurable results. The pharmaceutical environment is turbulent, and what used to work to create an industry wide growth of 20 percent, no longer does.Stauber Names Jim Freeman as Director of Sales and Marketing
FULLERTON, Calif. -- Stauber Performance Ingredients, Inc., announced today the appointment of Jim Freeman to the position of Director of Sales and Marketing. The position reports to John Milazzo, President of Stauber, and became effective on August 30, 2006.
